NO324382B1 - Kombinasjon av endotelinantagonist og en reninangiotensinsystem(RAS)-inhibitor, farmasoytisk preparat som omfatter kombinasjonen, samt fremstilling av preparatet og anvendelse av kombinasjonen. - Google Patents

Kombinasjon av endotelinantagonist og en reninangiotensinsystem(RAS)-inhibitor, farmasoytisk preparat som omfatter kombinasjonen, samt fremstilling av preparatet og anvendelse av kombinasjonen. Download PDF

Info

Publication number
NO324382B1
NO324382B1 NO20001548A NO20001548A NO324382B1 NO 324382 B1 NO324382 B1 NO 324382B1 NO 20001548 A NO20001548 A NO 20001548A NO 20001548 A NO20001548 A NO 20001548A NO 324382 B1 NO324382 B1 NO 324382B1
Authority
NO
Norway
Prior art keywords
combination
preparation
inhibitor
ras
endothelin antagonist
Prior art date
Application number
NO20001548A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001548L (no
NO20001548D0 (no
Inventor
Michael Kirchengast
Klaus Muenter
Horst Korioth
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19742717A external-priority patent/DE19742717A1/de
Priority claimed from DE1997143141 external-priority patent/DE19743141A1/de
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of NO20001548L publication Critical patent/NO20001548L/no
Publication of NO20001548D0 publication Critical patent/NO20001548D0/no
Publication of NO324382B1 publication Critical patent/NO324382B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20001548A 1997-09-26 2000-03-24 Kombinasjon av endotelinantagonist og en reninangiotensinsystem(RAS)-inhibitor, farmasoytisk preparat som omfatter kombinasjonen, samt fremstilling av preparatet og anvendelse av kombinasjonen. NO324382B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19742717A DE19742717A1 (de) 1997-09-26 1997-09-26 Pharmazeutische Kombinationspräparate
DE1997143141 DE19743141A1 (de) 1997-09-30 1997-09-30 Pharmazeutische Kombinationspräparate
PCT/EP1998/005773 WO1999016445A1 (fr) 1997-09-26 1998-09-10 Antagoniste d'endotheline et systeme renine-angiotensine inhibiteur presentes sous forme de preparation pharmaceutique

Publications (3)

Publication Number Publication Date
NO20001548L NO20001548L (no) 2000-03-24
NO20001548D0 NO20001548D0 (no) 2000-03-24
NO324382B1 true NO324382B1 (no) 2007-10-01

Family

ID=26040370

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001548A NO324382B1 (no) 1997-09-26 2000-03-24 Kombinasjon av endotelinantagonist og en reninangiotensinsystem(RAS)-inhibitor, farmasoytisk preparat som omfatter kombinasjonen, samt fremstilling av preparatet og anvendelse av kombinasjonen.

Country Status (15)

Country Link
US (1) US6329384B1 (fr)
EP (1) EP1014989B1 (fr)
JP (2) JP4917707B2 (fr)
KR (1) KR100623121B1 (fr)
CN (1) CN1187050C (fr)
AT (1) ATE257706T1 (fr)
AU (1) AU750755B2 (fr)
BR (1) BR9812531A (fr)
CA (1) CA2304712C (fr)
CZ (1) CZ299741B6 (fr)
DE (1) DE59810600D1 (fr)
ES (1) ES2214734T3 (fr)
HU (1) HU226454B1 (fr)
NO (1) NO324382B1 (fr)
WO (1) WO1999016445A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
CA2304712C (fr) * 1997-09-26 2008-04-29 Knoll Aktiengesellschaft Antagoniste d'endotheline et systeme renine-angiotensine inhibiteur presentes sous forme de preparation pharmaceutique
JP2009256209A (ja) * 2006-02-17 2009-11-05 Gilead Colorado Inc 降圧療法
AU2007217100A1 (en) * 2006-02-17 2007-08-30 Gilead Colorado, Inc. Antihypertensive therapy
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
CA2668724A1 (fr) * 2006-11-09 2008-05-22 Gilead Colorado, Inc. Forme posologique orale de darusentan
US20080139483A1 (en) * 2006-12-12 2008-06-12 Gorczynski Richard J Drug combination for hypertensive disorders
EP2545920A1 (fr) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Thérapie pour complications du diabète
US20090076119A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched ramipril
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0617001B1 (fr) * 1993-03-19 2000-01-26 Merck & Co. Inc. Dérivés d'acide phénoxyphénylacétique
DK0634175T3 (da) * 1993-07-15 2001-04-30 Hoffmann La Roche Farmaceutisk kombination, der indeholder en hæmmer af renin-angiotensin-systemet og en endothelin-antagonist
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
EP2301562B1 (fr) 1994-12-12 2013-04-17 Omeros Corporation Solution d'irrigation et utilisation de celle-ci pour inhiber périopérativement la douleur, l'inflammation et/ou les spasmes
PL184060B1 (pl) 1995-01-27 2002-08-30 Rhone Poulenc Rorer Ltd Podstawione związki fenylowe do zastosowania jako środki antagonistyczne endoteliny
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
DE19652374A1 (de) * 1996-12-04 1998-06-10 Schering Ag Verwendung von Endothelin-Konjugaten in der Therapie, neue Endothelin-Konjugate, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
ID26234A (id) * 1996-12-18 2000-12-07 Basf Ag Turunan-turunan asam karboksilat heterosiklik, pembuatan dan penggunaannya sebagai antagonis-antagonis reseptor endotelen
CA2304712C (fr) * 1997-09-26 2008-04-29 Knoll Aktiengesellschaft Antagoniste d'endotheline et systeme renine-angiotensine inhibiteur presentes sous forme de preparation pharmaceutique

Also Published As

Publication number Publication date
CN1271283A (zh) 2000-10-25
AU750755B2 (en) 2002-07-25
HU226454B1 (en) 2008-12-29
BR9812531A (pt) 2000-07-25
JP2001517704A (ja) 2001-10-09
CA2304712A1 (fr) 1999-04-08
ATE257706T1 (de) 2004-01-15
WO1999016445A1 (fr) 1999-04-08
HUP0004298A3 (en) 2002-06-28
CN1187050C (zh) 2005-02-02
AU9539598A (en) 1999-04-23
JP4917707B2 (ja) 2012-04-18
ES2214734T3 (es) 2004-09-16
US6329384B1 (en) 2001-12-11
NO20001548L (no) 2000-03-24
JP2012046531A (ja) 2012-03-08
CZ299741B6 (cs) 2008-11-05
EP1014989A1 (fr) 2000-07-05
DE59810600D1 (de) 2004-02-19
EP1014989B1 (fr) 2004-01-14
KR100623121B1 (ko) 2006-09-12
CZ20001107A3 (cs) 2000-08-16
CA2304712C (fr) 2008-04-29
HUP0004298A2 (hu) 2001-11-28
KR20010030713A (ko) 2001-04-16
NO20001548D0 (no) 2000-03-24

Similar Documents

Publication Publication Date Title
JP2012046531A (ja) 医薬組合せ剤
KR100370181B1 (ko) 약학적혼합제제
Kirk Angiotensin-II receptor antagonists: their place in therapy
KR20260037123A (ko) 엔도텔린 관련 질병의 치료를 위한 sglt-2 저해제와의 4-피리미딘설파미드 유도체의 병용
K. Vyas et al. Substituted benzimidazole derivatives as angiotensin II-AT1 receptor antagonist: a review
Hilal-Dandan Renin and angiotensin
EP1313468A2 (fr) Combinaison pharmaceutique d'antagonistes de l'angiotensine ii et d'inhibiteurs de l'enzyme de conversion de l'angiotensine i
Morganti et al. Aliskiren: the first direct renin inhibitor available for clinical use
JP2005501815A (ja) 治療方法
ES2213296T3 (es) Uso de un antagonista del receptor de angiotensina ii para la preparacion de medicamentos para aumentar la tasa de supervivencia de pacientes con trasplante renal.
RU2662565C2 (ru) Комбинированный фармацевтический препарат, содержащий блокатор рецептора ангиотензина-II и ингибитор ГМГ-КоА редуктазы
Opie et al. Inhibitors of the renin-angiotensin-aldosterone system
RU2222328C2 (ru) Фармацевтические комбинированные препараты
Brooks et al. Effect of captopril and the nonpeptide angiotensin II antagonists, SK&F 108566 and EXP3174, on renal function in dogs with a renal artery stenosis.
MXPA00002655A (en) Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation
Martineau et al. New Competition in the Realm of Renin—Angiotensin Axis Inhibition; the Angiotensin II Receptor Antagonists in Congestive Heart Failure
MOINuddIN et al. Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressure-overload rats: cardiovascular topics
Burnier et al. Angiotensin II receptor antagonists-antihypertensive agents
HRP20030124A2 (en) Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
WO2003007964A1 (fr) Remede ou agent preventif de cardiopathie ou d'anevrysme contenant un compose d'inhibition de la chymase
Angiotetisin Angiotensin|| receptors onc Ongiofensin ll blockers
AU2007237280A1 (en) Pharmaceutical combination of Angiotensin II antagonists and Angiotensin I converting enzyme inhibitors

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBVIE DEUTSCHLAND GMBH & CO AG, DE

MM1K Lapsed by not paying the annual fees